ENTA News Alert Enanta Pharmaceuticals Inc (ENTA) 33.30 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 2:49 AM

Enanta Pharmaceuticals Inc (ENTA) 33.30 $ENTA

AbbVie files NDA in Japan for 12-week once-daily HCV combo med
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 10:25AM CST

GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44)

Enanta Announces AbbVie Submits New Drug Application to the Japanese Ministry of Health, Labour and Welfare for its Investigational, All-Oral, Treatment for Chronic Hepatitis C
Business Wire - Thu Feb 12, 5:30AM CST
--12- week, two-direct-acting antiviral treatment regimen consists of paritaprevir/ritonavir and ombitasvir, dosed once daily
ENTA: 33.30 (-0.44)

AbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C
PR Newswire - Wed Feb 11, 9:04PM CST
AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily. The submission is for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection.
ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44)

Enanta Pharmaceuticals Risks Being Left Behind In The HCV Race
Clinically Sound Investor - at Seeking Alpha - Wed Feb 11, 11:58AM CST

ENTA: 33.30 (-0.44)

Does This Small Biotech Have the Making of a Blockbuster?
Motley Fool Staff - Motley Fool - Sat Feb 07, 8:59AM CST
Source: Flickr user Stockmonkeys.com. When it comes to developing billion-dollar blockbuster drugs, the odds are stacked against biotech companies. About 90% of drugs that enter clinical trials fail, and of those that do eventually get approved,...
OPHT: 51.11 (+0.12), ICPT: 209.12 (+7.12), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 4:37PM CST

FLIR: 33.01 (-0.23), ETR: 79.12 (-1.53), BCRX: 10.06 (-0.09), MCK: 224.89 (+0.12), HCN: 77.12 (-0.33), QUIK: 2.17 (+0.01), WAC: 20.29 (+2.57), RUSS: 11.59 (-0.81), ENTA: 33.30 (-0.44), LPI: 13.25 (+0.81)

Enanta Pharma ups earnings 878% in FQ2
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 11:26AM CST

ENTA: 33.30 (-0.44)

Enanta Pharmaceuticals misses Street 1Q forecasts
Automated Insights - Thu Feb 05, 9:27AM CST
WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Thursday reported fiscal first-quarter net income of $42 million, after reporting a loss in the same period a year earlier.
ENTA: 33.30 (-0.44)

Enanta Pharmaceuticals to Present at 2015 Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 7:00AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat, or question and answer session, with investors on February 12, 2015 at 10:45 a.m. ET during the 2015 Leerink Global Healthcare Conference in New York.
ENTA: 33.30 (-0.44)

Enanta Pharma misses by $1.64, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 6:49AM CST

ENTA: 33.30 (-0.44)

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2014
Business Wire - Thu Feb 05, 6:30AM CST
--GAAP earnings of $2.18 per diluted common share
ENTA: 33.30 (-0.44)

Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), OPHT: 51.11 (+0.12), LMNX: 15.45 (+0.02), ENTA: 33.30 (-0.44), ORPN: 7.17 (+0.04), EVOK: 5.41 (-0.10), RCII: 30.49 (+0.92), SCYX: 9.48 (+0.07), SSYS: 67.16 (-0.34), AKBA: 9.32 (+0.51), VBLT: 14.11 (+0.24)

Enanta Pharmaceuticals (ENTA) Falls: Stock Tanks 10% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 7:43AM CST
Make sure to keep a close watch on Enanta Pharmaceuticals in the near future, and especially on earnings estimates following the recent slump.
ENTA: 33.30 (-0.44)

Enanta Announces 95 percent SVR12 rate in AbbVie's Phase 3 Study of All-Oral Treatment for Hepatitis C Virus in Japanese Patients
Business Wire - Mon Feb 02, 6:30AM CST
--95 percent SVR12 rate achieved in Japanese patients new to therapy with genotype 1b chronic hepatitis C virus infection without cirrhosis and with a high viral load
ENTA: 33.30 (-0.44)

AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan
PR Newswire Europe - Fri Jan 30, 5:00PM CST
- 95 percent SVR(12) rate achieved in Japanese patients new to therapy with genotype 1b chronic hepatitis C virus infection without cirrhosis and with a high viral load
ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44)

Insider Trading Alert - ENTA, ATSG And SWN Traded By Insiders
at The Street - Wed Jan 21, 9:02AM CST
Stocks with insider trader activity include ENTA, ATSG and SWN
ATSG: 8.74 (+0.26), ENTA: 33.30 (-0.44), SWN: 27.36 (+0.51)

AbbVie HCV treatment cleared in Europe
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 6:58AM CST

GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44)

Enanta Announces European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets)...
Business Wire - Fri Jan 16, 6:00AM CST
Enanta Announces European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) for the Treatment of Genotypes 1 and 4 Chronic Hepatitis C Virus
ENTA: 33.30 (-0.44)

European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) for the Treatment of Chronic Hepatitis C
PR Newswire Europe - Fri Jan 16, 1:00AM CST
- In Phase 3 clinical trials, VIEKIRAX + EXVIERA cured 95-100 percent of genotype 1 chronic hepatitis C patients, with less than 2 percent of patients experiencing virologic failure[1],[2]
ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...